Analysis reveals that t(11;14) positive patients exhibit slower MRD negativity, but better progression-free survival, suggesting implications for treatment approaches.
Key Points
Median age of patients was 62 years, with 16% exhibiting t(11;14) positive multiple myeloma.
At the 10-5 threshold, MRD negativity rates significantly differed, 9% for t(11;14) positive versus 31% for t(11;14) negative patients post-induction.
A multivariate analysis indicated that both sustained MRD negativity and t(11;14) positive status correlate with a lower risk of disease progression or death.
Progression-free survival at four years was 93% for t(11;14) positive patients, demonstrating their outstanding prognosis post-QUAD therapy.